agree. I'm guessing that this article combined with the massive position taken by NAB to then on lend to Mac bank and others - most likely for shorting purposes is the reason for today's big move.
I'm not totally across the science here but i thought an issue with orally taken testosterone was that it was not as effective as injections, transdermal and had issues with liver damage...
The FDA has previously had issues... will be interesting to see if they can get it through the process.
I also think the articles over credits the ability of this firm to gain market share - granted if they get it through an oral form may have strong appeal but they would still be up against two very large and well-funded players in this space.
As a holder i continue to watch with interest.
ACR Price at posting:
$2.40 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)